1-3 of 3
Cecelia R. Miller
Close
Sort by
Journal Articles

Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization

Samantha M. Teierle, Ying Huang, Adam S. Kittai, Seema A. Bhat, Michael Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R. Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia R. Miller
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7239–7242.
https://doi.org/10.1182/bloodadvances.2023010753
Published: 2023
Includes: Supplemental data
Journal Articles

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

Clinical Trials & Observations
Jonathan M. Hyak, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Michael R. Grever, John C. Byrd, Adam S. Kittai, Dan Jones, Cecelia R. Miller, Jennifer A. Woyach
Journal: Blood Advances
Blood Adv (2022) 6 (17): 5124–5127.
https://doi.org/10.1182/bloodadvances.2022007708
Published: 2022
Includes: Supplemental data
Journal Articles

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib

Clinical Trials & Observations
Cecelia R. Miller, Amy S. Ruppert, Nyla A. Heerema, Kami J. Maddocks, Jadwiga Labanowska, Heather Breidenbach, Gerard Lozanski, Weiqiang Zhao, Amber L. Gordon, Jeffrey A. Jones, Joseph M. Flynn, Samantha M. Jaglowski, Leslie A. Andritsos, Kristie A. Blum, Farrukh T. Awan, Kerry A. Rogers, Michael R. Grever, Amy J. Johnson, Lynne V. Abruzzo, Erin K. Hertlein, James S. Blachly, Jennifer A. Woyach, John C. Byrd
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1584–1588.
https://doi.org/10.1182/bloodadvances.2017007302
Published: 2017
Includes: Supplemental data